Transcatheter Mitral Valve Replacement for Severe Mitral Regurgitation: A Global Study

Transcatheter Mitral Valve Replacement for Severe Mitral RegurgitationSymptomatic mitral regurgitation is associated with high morbidity and mortality that can be alleviated partly by surgical mitral valve replacement. However, many patients do not undergo surgery. Transcatheter mitral valve replacement is an appealing option for this selected patient group.

 

This study aimed to examine the effectiveness and safety of transcatheter mitral valve replacement in a cohort of patients with native valve mitral regurgitation and high surgical risk.

 

Patients undergoing transapical transcatheter mitral valve replacement with a self-expanding prosthesis were prospectively enrolled and their short-term (30-day) outcomes were assessed.

 

Thirty high-surgical-risk patients (STS predicted risk of mortality score of 7.6 ± 5.7%) with grade 3 or 4 mitral regurgitation received the device, and there was successful implantation in 28 of them (93.3%).

 

There were no deaths, strokes, or peri-procedural infarctions. One patient died at 13 days from a hospital-acquired infection. One patient presented leaflet thrombosis that was resolved by increasing the range of anticoagulation with warfarin.

 

At 30 days, an echocardiography showed mild regurgitation in 1 patient, and absolutely none in the remaining 26 patients. There was also a significant reduction in the left ventricular end-diastolic and end-systolic volume indexes.

 

Seventy-five percent of the patients reported mild or no symptoms at follow-up.

 

Successful device implantation free of mortality, stroke, and prosthesis malfunction was 86.6%.

 

Conclusion

Transcatheter mitral valve replacement is an effective and safe therapy for selected patients with severe mitral regurgitation and high surgical risk.

 

Original title: Transcatheter Mitral Valve Replacement for Patients with Symptomatic Mitral Regurgitation. A Global Feasibility Trial.

Reference: David W.M. Muller et al. J Am Coll Cardiol. 2016 Dec 20. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...